Hosted on MSN
Study backs Alterity’s innovative tool in diagnosing and monitoring MSA disease progression
Quality peer-reviewed publication highlights use of Alterity’s MSA Atrophy Index developed to diagnose and track MSA disease progression Tool helps pinpoint changes in brain over time, making it ...
Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol - - FDA agreed that a single pivotal Phase 3 trial ...
Multiple system atrophy (MSA) is a progressive neurological condition that affects movements and involuntary functions, such as blood pressure and digestion. The first symptoms of MSA resemble those ...
Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results